Author(s):
Pamela Kusumadewi Putri Thaib, Anny Setijo Rahaju, Etty Hary Kusumastuti
Email(s):
anny_sr@fk.unair.ac.id
DOI:
10.52711/0974-360X.2023.00140 
Address:
Pamela Kusumadewi Putri Thaib1,2,3, Anny Setijo Rahaju1,2,3*, Etty Hary Kusumastuti1,3
1Department of Anatomical Pathology, Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia.
2Universitas Airlangga Academic Hospital, Surabaya, Indonesia.
3Dr. Soetomo General Academic Hospital, Surabaya, Indonesia.
*Corresponding Author
Published In:
Volume - 16,
Issue - 2,
Year - 2023
ABSTRACT:
Clear cell renal cell carcinoma (ccRCC) is the most common type of kidney cancer with high mortality. Escalation of T stage associates with worse survival. Proper and significant biomarker examination necessary to determine the predictive factor and the opportunity of targeted therapy as well. Upregulated CXCR4 expression on cancer cell promotes its aggressive growth, dissemination, metastasis, and conventional therapy resistance. Overexpression of CXCR4 may induce MMP-2 activity on tumor cell, an enzyme that degrade extracellular matrix and basal membrane particularly, which associated with tumor invasion and metastasis. Those biomarkers activity might be advantaged under hypoxic microenvironment in ccRCC. This study aimed to analyze the role and correlation of CXCR4 and MMP-2 expression with various T stages in ccRCC. Analytic observational study with cross-sectional approach was conducted on 43 formalin-fixed paraffin-embedded tissue of patients diagnosed as ccRCC in Anatomical Pathology Laboratory of Dr. Soetomo Hospital throughout January 2015 until December 2020. CXCR4 and MMP-2 expression were evaluated by immunohistochemistry. Statistical analysis with Kruskal-Wallis and Spearman test were utilized to analyze the expression difference and correlation. Difference of both CXCR4 (p=0.016) and MMP-2 (p=0.029) expression were obtained on various T stages. There was a significant positive correlation between CXCR4 expression (p=0.001) and MMP-2 expression (p=0.002) with T stage, also between CXCR4 with MMP-2 expression in various T stage of ccRCC (p=0.000). In conclusion, this study exhibited that CXCR4 and MMP-2 expression showed synergistic and positive correlation with T stage and might be considered as the basis of targeted therapy in ccRCC.
Cite this article:
Pamela Kusumadewi Putri Thaib, Anny Setijo Rahaju, Etty Hary Kusumastuti. Correlation between CXCR4 and MMP-2 Expression with T Stage in Clear Cell Renal Cell Carcinoma. Research Journal of Pharmacy and Technology 2023; 16(2):821-9. doi: 10.52711/0974-360X.2023.00140
Cite(Electronic):
Pamela Kusumadewi Putri Thaib, Anny Setijo Rahaju, Etty Hary Kusumastuti. Correlation between CXCR4 and MMP-2 Expression with T Stage in Clear Cell Renal Cell Carcinoma. Research Journal of Pharmacy and Technology 2023; 16(2):821-9. doi: 10.52711/0974-360X.2023.00140 Available on: https://www.rjptonline.org/AbstractView.aspx?PID=2023-16-2-59
REFERENCES:
1. Dharmawan MA, Ansori ANM, Dian FA, Probojati RT, Tamam MB, Kharisma VD. Vaccine construction for human papilloma virus (HPV) type 16 and 18 Infection using in silico approach to combat cervical cancer. Genbinesia Journal of Biology. 2021; 1(1): 13-22.
2. Padala, S.A., Barsouk, A., Thandra K.C., Saginala, K., Mohammed, A., Vakiti, A., Rawla, P., and Barsouk, A. 2020. ‘Epidemiology of renal cell carcinoma’. World J Oncol, 11(3), pp. 79–87. doi:10. 14740/ wjon1279
3. Hakimi, A.A., Reznik, E., Lee, C., Creighton, C.J., Brannon, A.R., Luna, A., Aksoy, B.A., Liu, E.M., Shen, R., Lee, W., Chen, Y., Stirdivant, S.M., Russo, P., Chen, Y., Tickoo, S.K., Reuter, V.E., Cheng, E.H., Sander, C., and Hsieh, J.J. 2016. ‘An integrated metabolic atlas of clear cell renal cell carcinoma’. Cancer Cell, 29(1), pp.104-116. doi: 10.1016/j.ccell.201512.004
4. GLOBOCAN. 2020. ‘The global cancer observatory: cancer today’. Lyon, France: World Health Organization International Agency for Research on Cancer (IARC). https://gco.iarc.fr/today. Accessed March 2, 2021.
5. Hsieh, J.J., Purdue, M.P., Signoretti, S., Swanton, C., Albiges, L., Schmidinger, M., Heng, D.Y., Larkin, J., and Ficarra, V. 2017. ‘Renal cell carcinoma’. Nat Rev Dis Primers 3, 17009(1). doi: 10.1038/nrdp.2017.9
6. Bergstrom, A., Hsieh, J.J., Lindbald, P., Lu, C.M, Cook, N.R., and Wolk, A. 2001. ‘Obesity and renal cell cancer-a quantitative review’. Br J Cancer, 85(7), pp. 984-990. doi: 10.1054/bjoc.2001.2040
7. Ferlay, J., Steliarova-Foucher, E., Lortet-Tieulent, J., Rosso, C., Coebergh, J.W.W., Comber, H., Forman, D., and Bray, F. 2013. ‘Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012’. Eur J Cancer, 49(6), pp. 1374-1403. doi: 10.1016/j.ejca.2012.12.027
8. Rini, B.I., Campbell, S.C., and Escudier, B. 2009. ‘Renal cell carcinoma’. Lancet, 373, pp. 1119-32. doi: 10.1016/S0140-6736(09)60229-4
9. Brugarolas, J. 2014. ‘Molecular genetics of clear-cell renal cell carcinoma’. J Clin Oncol, 32(18), pp.1968-1976. doi: 10.1200/JCO.2012.45.2003
10. Erdogan, F., Demirel, A., and Polat, O. 2004. ‘Prognostic significance of morphologic parameters in renal cell carcinoma’. Int J Clin Pract, 58(4), pp. 333-336. doi: 10.1111/j.1368-5031.2004.00008.x
11. Taneja, K. and Williamson, S.R. 2018. ‘Updates in pathologic staging and histologic grading of renal cell carcinoma’. Surgical Pathology Clinics, 11(4), pp.797-812. doi: 10.1016/j.path.2018.07.004
12. Rini, B.I., McKieman, J.M., and Chang, S.S. 2017. ‘Kidney’. AJCC cancer staging manual. 8th ed. Switzerland: Springer, pp.739-48.
13. Lombardi, L., Tavano, F., Morellia, F., Latiano, T.P., Sebastiano, P.D., and Maiello, E. 2013. ‘Chemokine receptor CXCR4: Role in gastrointestinal cancer’. Critical Reviews in Oncology/Hematology, 88(3), pp.696–705. doi: 10.1016/j.critrevonc.2013.08.005
14. Chatterjee, S., Azad, B.B., and Nimmagadda, S. 2014. ‘Chapter two-The intricate role of CXCR4 in cancer’. Advances in Cancer Research, 124, pp.31-82. doi:10.1016/B978-0-12-411638-2.00002-1
15. Richard, C.L., Tan, E.Y., and Blay, J. 2006. ‘Adenosine upregulates CXCR4 and enhances the proliferative and migratory responses of human carcinoma cells to CXCL12/SDF-1α’. Int. J. Cancer, 119(9), pp. 2044-53. doi: 10.1002/ijc.22084
16. Rasti, A., Abolhasani, M., Zanjani L, S., Asgari, M., Mehrazma, M., and Madjd, Z. 2017. ‘Reduced expression of CXCR4, a novel renal cancer stem cell marker, is associated with high-grade renal cell carcinoma. J Cancer Res Clin Oncol, 143, pp. 95-104. doi: 10.1007/s00432-016-2239-8
17. Staller, P., Sulitkova, J., Lisztwan, J., Moch, H., Oakeley, E.J., and Krek, W. 2003. ‘Chemokine receptor CXCR4 downregulated by von Hippel-Lindau tumour suppressor pVHL’. Nature, 425(6955), pp. 307-11. doi: 10.1038/nature01874
18. Zagzag, D., Krishnamachary, B., Yee, H., Okuyama, H., Chiriboga, L., Ali, M.A., Melamed, J., and Semenza, G.L. 2005. ‘Stromal cell-derived factor-1α and CXCR4 expression in hemangioblastoma and clear cell-renal cell carcinoma: von Hippel-Lindau loss-of-function induces expression of a ligand and its receptor’. Cancer Res, 65(14), pp.6178-6188. doi: 10.1158/0008-5472.CAN-04-4406
19. Li, G., Badin, G., Zhao, A., Gentil-Perret, A., Tostain, J., Peoc’h, M., and Gigante, M. 2013. ‘Prognostic value of CXCR4 expression in patients with clear cell renal cell carcinoma’. Histology and Histopathology, 28(9), pp.1217–1222.
20. Scotton, C.J., Wilson, J.L., Milliken, D., Stamp, G., and Balkwill, F.R. 2001. ‘Epithelial cancer cell migration’. Cancer Res, 61(13), pp. 4961-65.
21. Ghosh, M.C., Makena, P.S., Gorantla, V., Sinclair, S.E., and Waters, C.M. 2012. ‘CXCR4 regulates migration of lung alveolar epithelial cells through activation of Rac1 and matrix metalloproteinase-2’. Am J Physiol Lung Cell Mol Physiol, 302, pp. L846-L856. doi:10.1152/ajplung.00321.2011
22. Zhu, X., Bai, Q., Lu, Y., Lu, Y., Zhu, L., Zhou, X., and Wu, L. 2016. ‘Expression and function of CXCL12/CXCR4/CXCR7 in thyroid cancer’. International Journal of Oncology, 48(6), pp.2321-2329. doi:0.3892/ijo.2016.3485
23. Struckmann, K., Mertz, K., Steu, S., Storz, M., Staller, P., Krek, W., Schraml, P., and Moch, H. 2008. ‘pVHL co-ordinately regulates CXCR4/CXCL12 and MMP2/MMP9 expression in human clear-cell renal cell carcinoma’. The Journal of Pathology, 214(4), 464-71. doi: 10.1002/path.2310
24. Hua, H., Li, M., Luo, T., Yin, Y., and Jiang, Y. 2011. ‘Matrix metalloproteinases in tumorigenesis: an evolving paradigm’. Cell. Mol. Life Sci., 68, pp.3853–3868. doi: 10.1007/s00018-011-0763-x
25. Sleightholm, R.L., Neilsen, B.K., Li, J., Steele, M.M., Singh, R.K., Hollingsworth, M.A., and Oupicky, D. 2017. ‘Emerging roles of the CXCL12/CXCR4 axis in pancreatic cancer progression and therapy’. Pharmacology & Therapeutics, 179, pp.158–170. doi: 10.1016/j.pharmthera.2017.05.012
26. Akashi, T., Koizumi, K., Tsuneyama, K., Saiki, I., Takano, Y., and Fuse, H. 2008. ‘Chemokine receptor CXCR4 expression and prognosis in patients with metastatic prostate cancer’. Cancer Science, 99(3), pp.539–542. doi:10.1111/j.1349-7006.2007.00712.x
27. Sun, Y., Mao, X., Fan, C., Liu, C., Guo, A., Guan, S., JIn, Q., Li, B., Yao, F., and Jin, F. 2014. ‘CXCL12-CXCR4 axis promotes the natural selection of breast cancer cell metastasis’. Tumor Biol., 35, pp.7765–7773. doi:10.1007/s13277-014-1816-1
28. Ottaiano, A., Santorsola, M., Del Prete, P., Perri, F., Scala, S., Caraglia, M., and Nasti, G. 2021. ’Prognostic significance of CXCR4 in colorectal cancer: An updated meta-analysis and critical appraisal’. Cancers, 13, pp. 3284. doi:10.3390/cancers13133284
29. Guntarno, N.C., Rahaju, A.S., and Kurniasari, N. 2021. ‘The role of MMP-9 and VEGF in the invasion state of bladder urothelial carcinoma’. Indones Biomed, 13(1), pp.61-67. doi: 10.18585/inabj.v13i1.1348
30. Hambalie, L.A., Rahaju, A.S., and Mastutik, G. 2021. ‘The correlation of EMMPRIN and EGFR overexpression toward muscle invasiveness in urothelial carcinoma of bladder’. Indian Journal of forensic medicine & toxicology, 15(2), pp.2709-2715.
31. Ramadhani, V.Y., Rahaju, A.S., and Kurniasari, N. 2021. ‘The role of EMPPRIN in perirenal fat invasion clear cell renal cell carcinoma’. Indian Journal of Forensic Medicine & Toxicology, 15(1), pp.1633-1639.
32. Hamid, A.R.A.H., Umbas, R., Oka, A.A.G., Mochtar, C.A., Djatisoesanto, W., Soedarso, M.A., Safriadi, F., Danarto, H.R., Warli, S.M., Ali, A.Z., Seputra, K.P., Sihombing, A.T., and Hakim, L. 2019. Pedoman Tata Laksana Kanker Ginjal. 2nd ed. DKI Jakarta: Ikatan Ahli Urologi Indonesia (IAUI).
33. Wehler, T.C., Graf, C., Biesterfeld, S., Brenner, W., Schadt, J., Gockel, I., Berger, M.R., Thüroff, J.W., Galle, P.R., Moehler, M., and Schimanski, C.C. 2008. ‘Strong expression of chemokine receptor CXCR4 by renal cell carcinoma correlates with advanced disease’. Journal of Oncology, ID 626340, pp.1-6. doi:10.1155/2008/626340
34. An, H., Xu, L., Zhu, Y., Lv, T., Liu, W., Liu, Y., Liu, H., Chen, L., Xu, J., and Lin, Z. 2014. ‘High CXC chemokine receptor 4 expression is an adverse prognostic factor in patients with clear-cell renal cell carcinoma’. Br J Cancer, 110, pp. 2261–2268. doi: 10.1038/bjc.2014.179
35. Wang, L., Wang, Z., Yang, B., Yang, Q., Wang, L., and Sun, Y. 2009. ‘CXCR4 nuclear localization follows binding of its ligand SDF-1 and occurs in metastatic but not primary renal cell carcinoma’. Oncology Reports, 22, pp.1333-1339. https://doi.org/10.3892/or_00000572
36. Floranović, M.P., Petrović, A.R., Veličković, F., and Veličković, L.J. 2021. ‘Expression and prognostic value of CXCL12/CXCR4/CXCR7 axis in clear cell renal cell carcinoma’. Clin Exp Nephrol, 25, pp.1057–1069. doi:10.1007/s10157-021-02081-0
37. Octavianda, Y. and Rahaju, A.S. 2018. ‘Increased HIF-1α and VEGF expression found in various T stages of clear cell renal cell carcinoma’. Folia Medica Indonesiana, 54(2), pp.102-107. doi: 10.20473/fmi.v54i2.8858
38. Du, Y., Long, Q., Guan, B., and Mu, L. 2015. ‘Prognostic value of high CXCR4 expression in renal cell carcinoma: A system review and meta-analysis’. Disease Markers, 2015(568980). doi: 10.1155/2015/568980
39. Bachelder, R.E., Wendt, M.A., and Mercurio, A.M. 2002. ‘Vascular endothelial growth factor promotes breast carcinoma invasion in an autocrine manner by regulating the chemokine receptor CXCR4’. Cancer Res, 62(24), pp. 7203-7206.
40. Teicher, B.A. and Fricker, P.S. 2010. ‘CXCL12(SDF-1)/CXCR4 pathway in cancer’. Clin Cancer Res, 16(11), pp. 2927-2931. doi: 10.1158/1078-0432.CCR-09-2329
41. Duda, D.G., Kozin, S.V., Kirkpatrick, N.D., Xu, L., Fukumura, D., and Jain, R.K. 2011. ‘CXCL12 (SDF1α)-CXCR4/CXCR7 pathway inhibition: An emerging sensitizer for anticancer therapies?’. Clin Cancer Res, 17(8), pp.2074 -2080. doi: 10.1158/1078-0432.CCR-10-2636
42. Santagata, S., Ieranò, C., Trotta, A.M., Capiluongo, A., Auletta, F., Guardascione, G., and Scala, S. 2021. ‘CXCR4 and CXCR7 signaling pathways: A focus 83 on the cross-talk between cancer cells and tumor microenvironment’. Oncol, 11, pp.591386. doi:10.3389/fonc.2021.591386
43. Balshy, A.E.E., Maksoud, A.A.E., Sawi, R.E., and Nagieb, Y. 2021. ‘Significance of CXC chemokine receptor 4 (CXCR4) in Renal Cell Carcinoma’. Benha Medical Journal, 38(6), pp.73-91. doi: 10.21608/bmfj.2020.125160
44. D’Alterio, C., Cindolo, L., Portella, L., Polimeno, M., Consales, C., Riccio, A., Cioffi, M., Franco, R., Chiodini, P., Cartenì, G., Mirone, V., Longo, N., Marra, L., Perdonà, S., Claudio, L., Mascolo, M., Staibano, S., Falsaperla, M., Puglisi, M., Martignoni, G., Ficarra, V., Castello, G., and Scala, S. 2010a. ‘Differential role of CD133 and CXCR4 in renal cell carcinoma’. Cell Cycle, 9(22), pp.4492-4500. doi: 10.4161/cc.9.22.13680
45. Smith, M.C., Luker, K.E., Garbow, J.R., Prior, J.L., Jackson, E., Piwnica-Worms, D., and Luker, G.D. 2004. ‘CXCR4 regulates growth of both primary and metastatic breast cancer’. Cancer Res, 64(23), pp.8604–8612
46. De Falco, V., Guarino, V., Avilla, E., Castellone, M.D., Salerno, P., Salvatore, G., Faviana, P., Basolo, F., Santoro, M., and Melillo, R.M. 2007. ‘Biological role and potential therapeutic targeting of the chemokine receptor CXCR4 in undifferentiated thyroid cancer’. Cancer Res, 67(24), pp.11821-11829. doi: 10.1158/0008-5472.CAN-07-0899
47. Porvasnik, S., Sakamoto, N., Kusmartsev, S., Eruslanov, E., Kim, W.J., Cao, W., Urbanek, C., Wong, D., Goodison, S., and Rosser, C.J. 2009. ‘Effects of CXCR4 antagonist CTCE-9908 on prostate tumor growth’. Prostate, 69(13), pp.1460–1469. doi:10.1002/pros.21008
48. Cho, K.S., Yoon, S.J., Lee, J.Y., Cho, N.H., Choi, Y.D., Song, Y.S., and Hong, S.J. 2013. ‘Inhibition of tumor growth and histopathological changes following treatment with a chemokine receptor CXCR4 antagonist in a prostate cancer xenograft model’. Oncol Lett, 6(4), 933–938.
49. De Clercq, E. 2010. ‘Recent advances on the use of the CXCR4 antagonist plerixafor (AMD3100, MozobilTM) and potential of other CXCR4 antagonists as stem cell mobilizers’. Pharmacology & Therapeutics, 128(3), pp.509–518. doi: 10.1016/j.pharmthera.2010.08.009
50. Fricker, S.P., Anastassov, V., Cox, J., Darkes, M.C., Grujic, O., Idzan, S.R., Labrecque, J., Lau, G., Mosi, R.M., Nelson, K.L., Qin, L., Santucci, Z., and Wong, R.S.Y. 2006. ‘Characterization of the molecular pharmacology of AMD3100: A specific antagonist of the G-protein coupled chemokine receptor, CXCR4’. Biochemical Pharmacology, 72(5), pp.588–596. doi:10.1016/j.bcp.2006.05.010
51. Rosadi I, Karina K, Kharisma VD, Ansori ANM. L-ascorbic acid-2-phosphate and fibrin substrate enhances the chondrogenic differentiation of human adipose-derived stem cells. Progress in Stem Cell. 2021; 8(2): 310-317.
52. Kurban, G., Hudon, V., Duplan, E, Ohh, M., Pause, A. 2006. ‘Characterization of a von Hippel Lindau pathway involved in extracellular matrix remodeling, cell invasion, and angiogenesis’. Cancer Res 66, pp. 1313–1319. doi: 10.158/0008-5472.CAN-05-2560
53. Rotte, A., Martinka, M., and Li, G. 2012. ‘MMP2 expression is a prognostic marker for primary melanoma patients’. Cell Oncol, 35, pp.207-216. doi: 10.1007/s13402-012-0080-x
54. Kallakury, B.V., Karikehalli, S., Haholu, A., Sheehan, C.E., Ami, N., and Ross, J.S. 2001. ‘Increased expression of matrix metalloproteinases 2 and 9 and tissue inhibitors of metalloproteinases 1 and 2 correlate with poor prognostic variables in renal cell carcinoma’. Clin Cancer Res, 7, pp. 3113–3119.
55. Ahmad, S., Singh, V., Sinha, R.J., Srivastava, A., and Mandhani, A. 2018. ‘Role of MMP-2, MMP-9 and VEGF as serum biomarker in early prognosis of renal cell carcinoma’. African Journal of Urology, 24, pp.255-263. doi: 10.1016/j.afju.2018.09.003
56. Trudel, D., Fradet, Y., Meyer, F., Harel., F., and Tetu, B. 2003. ‘Significance of MMP-2 expression in prostate cancer: an immunohistochemical study’. Cancer Research, 63, pp.8511-8515.
57. Fatimah, S., Rahaju, A.S., and Rahniayu, A. 2021. ‘Role of Claudin-4 and Matrix Metalloproteinase-2 in tumor invasion of colorectal adenocarcinoma’. Research J. Pharm. and Tech., 14(9), pp.4795-4800. doi: 10.52711/0974-360X.2021.00834
58. Nagase, H., Visse, R., and Murphy, G. 2006. ‘Structure and function of matrix metalloproteinases and TIMPs’. Cardiovasc Res, 69(3), pp. 562–573. doi: 10.1016/j.cardiores.2005.12.002
59. Miller, K.D., Saphner, T.J., Waterhouse, D.M., Chen, T.-T., Rush-Taylor, A., Sparano, J.A., Wolff, A.C., Cobleigh, M.A., Galbraith, S., and Sledge, G.W. 2004. ‘A randomized phase II feasibility trial of BMS-275291 in patients with early breast cancer’. Clin Cancer Res, 10(6), pp.1971-1975. doi: 10.1158/1078-0432.CCR-03-0968
60. Leighl, N.B., Paz-Ares, L., Douillard, J.-Y., Peschel, C., Arnold, A., Depierre, A., Santoro, A., Betticher, D.C., Gatzemeier, U., Jassem, J., Crawford, J., Tu, D., Bezjak, A., Humphrey, J.S., Voi, M., Galbraith, S., Hann, K., Seymour, L., and Shepherd, F.A. 2005. ‘Randomized phase III study of matrix metalloproteinase inhibitor BMS-275291 in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: National cancer institute of Canada-clinical trials group study BR.18’. J Clin Oncol, 23, pp.2831-2839. doi: 10.1200/JCO.2005.04.044
61. Widyananda MH, Pratama SK, Samoedra RS, Sari FN, Kharisma VD, Ansori ANM, Antonius Y. Molecular docking study of sea urchin (Arbacia lixula) peptides as multi-target inhibitor for non-small cell lung cancer (NSCLC) associated proteins. J Pharm Pharmacogn Res. 2021; 9(4): 484-96.
62. Ramadhani NF, Nugraha AP, Ihsan IS, Agung YA, Rantam FA, Ernawati DS, Ridwan RD, Narmada IB, Ansori AN, Hayaza S, Noor TN. Gingival medicinal signaling cells conditioned medium effect on the osteoclast and osteoblast number in lipopolysaccharide-induced calvaria bone resorption in wistar rats’ (Rattus novergicus). Research Journal of Pharmacy and Technology. 2021; 14(10): 5232-7.
63. Frayyeh, A.H., Salman, E.D., and Melconian, A.K. 2019. ‘Elevated serum level of CXCR4 in breast cancer women’. Research J. Pharm. and Tech., 12(8), pp. 3833-3838.
64. Fadholly A, Ansori AN, Proboningrat A, Nugraha AP, Iskandar RP, Rantam FA, Sudjarwo SA. Apoptosis of hela cells via caspase-3 expression induced by chitosan-based nanoparticles of Annona squamosa leaf extract: In vitro study. Indian J. Pharm. Educ. Res. 2020; 54(2): 416-22.
65. Fadholly A, Ansori AN, Susilo RJ, Nugraha AP. Daphne genkwa sieb. et zucc. as anticancer of oral squamous cell carcinoma: A systematic review. Biochemical and Cellular Archives. 2020; 20: 2849-55.
66. Proboningrat A, Ansori AN, Fadholly A, Putri N, Kusala MK, Achmad AB. First report on the cytotoxicity of Pinus merkusii bark extract in WiDr, A human colon carcinoma cell line. Research Journal of Pharmacy and Technology. 2021; 14(3): 1685-8.
67. Pandey, P., and Kar, P.K. 2013. ‘Assessment of suitability of methods used in the diagnosis of carcinomas’. Research J. Pharmacology and Pharmacodynamics, 5(2), pp. 98-100.
68. Proboningrat A, Jayanti S, Fadholly A, Ansori AN, Putri N, Kusala MK, Sudjarwo SA, Rantam FA, Achmad AB. The cytotoxicity of ethanolic extract of Allium cepa L. on hela cell lines. Research Journal of Pharmacy and Technology. 2021; 14(9): 4969-72.
69. Fadholly A, Ansori AN, Jayanti S, Proboningrat A, Kusala MK, Putri N, Rantam FA, Sudjarwo SA. Cytotoxic effect of Allium cepa L. extract on human colon cancer (WiDr) cells: in vitro study. Research Journal of Pharmacy and Technology. 2019; 12(7): 3483-6.
70. Fadholly A, Ansori ANM, Utomo B. Anticancer effect of naringin on human colon cancer (widr cells): In vitro study. Research Journal of Pharmacy and Technology. 2022; 15(2):885-8. doi: 10.52711/0974-360X.2022.00148